All In Biotech

NDA 022488 · Upjohn

Lyrica

Pregabalin · Oral

Last checked: Nov 20, 2026Latest source record: Apr 25, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Jan 4, 2010

Approved uses

5

Original approval plus efficacy supplements

Registered trials

564

150 Phase 3, 40 recruiting

FAERS reports

273,908

183,607 serious, 22,698 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 15, 2025.

LYRICA is indicated for: • Management of neuropathic pain associated with diabetic peripheral neuropathy • Management of postherpetic neuralgia • Adjunctive therapy for the treatment of partial‑onset seizures in patients 1 month of age and older • Management of fibromyalgia • Management of neuropathic pain associated with spinal cord injury LYRICA is indicated for: • Neuropathic pain associated with diabetic peripheral neuropathy (DPN) ( 1 ) • Postherpetic neuralgia (PHN) ( 1 ) • Adjunctive therapy for the treatment of partial‑onset seizures in patients 1 month of age and older ( 1 ) • Fibromyalgia ( 1 ) • Neuropathic pain associated with spinal cord injury ( 1 )

Mechanism: LYRICA (pregabalin) binds with high affinity to the alpha 2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin) suggest that binding to the alpha 2 -delta subunit may be involved in pregabalin’s anti-nociceptive and antiseizure effects in animals. In animal models of nerve damage, pregabalin has been shown to reduce calcium-dependent release of...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • LYRICA · PREGABALIN 20MG/ML · SOLUTION, ORAL · Prescription · TE AA

Clinical trials

Interventional ClinicalTrials.gov studies with "Pregabalin" as an intervention, any sponsor and status, largest first.

All 564 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective27,200
  • pain26,508
  • fatigue15,853
  • dizziness15,031
  • nausea14,720
  • off label use14,004
  • headache13,242
  • malaise12,999
  • somnolence11,958
  • weight increased11,711
  • pain in extremity11,488
  • fall11,138

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045
2005351
20064,998
20072,871
20083,560
20093,001
201013,566
20116,904
201213,074
201314,156
201416,247
201518,634
201619,912
201718,062
201820,542
201922,875
202018,930
202114,842
202213,309
202311,934
202413,545
202513,013
20269,577

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lyrica (Pregabalin)

2024 spending

$62.0M

Beneficiaries

11,809

65,724 claims

Per beneficiary

$5,253

$9.67 per unit

View as table
YearSpending
2020$147,354,969
2021$90,904,463
2022$78,715,397
2023$71,720,875
2024$62,035,504

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,057 on PubMed

Sponsor: Upjohn

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.